<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01487330</url>
  </required_header>
  <id_info>
    <org_study_id>1103</org_study_id>
    <nct_id>NCT01487330</nct_id>
  </id_info>
  <brief_title>First in Human Experience of the St. Jude Medical TAVI Valve and Delivery System</brief_title>
  <acronym>SJM TAVI FIH</acronym>
  <official_title>First In Human Experience and Assessment of the 23mm SJM Transcatheter Aortic Valve Implant and the SJM TAVI Transfemoral Delivery System (SJM TAVI FIH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Abbott Medical Devices</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Abbott Medical Devices</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this first-in-human study is to assess the technical feasibility, deployment&#xD;
      characteristics, and safety of the 23mm SJM Transfemoral Transcatheter Heart Valve and&#xD;
      delivery system in subjects with severe symptomatic aortic stenosis (AS).&#xD;
&#xD;
      This is a single center, prospective, non-randomized, first-in-human investigational study&#xD;
      without concurrent or matched controls.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Data will be collected at baseline, procedure, discharge (date of hospital discharge or 7&#xD;
      days post-implant, whichever occurs first), 30 days post implant, 3 months post implant, 6&#xD;
      months post implant, and 12 months post implant.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2011</start_date>
  <completion_date type="Actual">September 2012</completion_date>
  <primary_completion_date type="Actual">October 2011</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of Technical Feasibility and Device Deployment Characteristics</measure>
    <time_frame>At time of procedure</time_frame>
    <description>Evaluate the technical feasibility and device deployment characteristics (observed at procedure) by:&#xD;
The ability for the valve to be deployed at the desired location&#xD;
The ability to complete the full procedure&#xD;
Quantification of the time from delivery system entry to a fully deployed and functional valve</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quantification of SAEs Reported (Device Related or Procedure Related)</measure>
    <time_frame>Through 12 months post implantation</time_frame>
    <description>Evaluate the safety of the 23mm SJM Transcatheter Aortic Heart Valve and transfemoral delivery system by:&#xD;
Summarizing the SAEs observed at procedure that are device or procedure related&#xD;
Summarizing the SAEs observed during the study</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">10</enrollment>
  <condition>Symptomatic Aortic Stenosis</condition>
  <arm_group>
    <arm_group_label>Subjects receiving TAVI valve</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Transcatheter Aortic Valve Implantation (TAVI)</intervention_name>
    <description>Placement of the SJM TAVI aortic valve with a transfemoral delivery system.</description>
    <arm_group_label>Subjects receiving TAVI valve</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Written Informed Consent for participation prior to procedure.&#xD;
&#xD;
          2. Legal age in host country.&#xD;
&#xD;
          3. Aortic annulus 19-21mm diameter&#xD;
&#xD;
          4. Senile degenerative aortic stenosis with derived mean gradient &gt;40mmHg or jet velocity&#xD;
             greater than 4.0 m/s or an initial valve area of &lt;1.0 cm2 (or aortic valve area index&#xD;
             ≤ 0.6 cm2/m2)&#xD;
&#xD;
          5. NYHA Functional Classification of II or greater.&#xD;
&#xD;
          6. Predicted operative mortality or serious, irreversible morbidity risk is &lt;50% at 30&#xD;
             days.&#xD;
&#xD;
          7. Suitable peripheral vessels and aorta to allow for access of the 18 French delivery&#xD;
             system.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of a cerebral vascular accident (CVA) or transient ischemic attack (TIA)&#xD;
             within the past 6 months (≤180 days) of index procedure.&#xD;
&#xD;
          2. Carotid artery disease requiring intervention.&#xD;
&#xD;
          3. Myocardial infarction (MI) within 6 months (≤180 days) of the index procedure.&#xD;
&#xD;
          4. Native aortic valve that is congenitally unicuspid, bicuspid, quadricuspid or&#xD;
             non-calcified as seen by echocardiography.&#xD;
&#xD;
          5. Mitral or tricuspid valvular regurgitation (grade II) or moderate to severe mitral&#xD;
             stenosis.&#xD;
&#xD;
          6. Aortic root angulation &gt;70 degrees (horizontal aorta).&#xD;
&#xD;
          7. Pre-existing prosthetic valve or prosthetic ring in any position. LVEF &lt; 20%.&#xD;
&#xD;
          8. Untreated coronary artery disease (CAD) requiring revascularization.&#xD;
&#xD;
          9. Severe basal septal hypertrophy.&#xD;
&#xD;
         10. Percutaneous interventional or other invasive cardiac or peripheral procedure ≤ 14&#xD;
             days or history of previous endocarditis.&#xD;
&#xD;
         11. Uncontrolled atrial fibrillation (AF) or is in chronic AF without long term oral&#xD;
             anticoagulation.&#xD;
&#xD;
         12. Evidence of intracardiac mass, thrombus, or vegetation.&#xD;
&#xD;
         13. Hemodynamic instability&#xD;
&#xD;
         14. Significant pulmonary disease.&#xD;
&#xD;
         15. Nonreactive pulmonary hypertension.&#xD;
&#xD;
         16. Chronic steroid use.&#xD;
&#xD;
         17. Hypersensitivity or contraindication to anticoagulant or antiplatelet medication.&#xD;
&#xD;
         18. Renal insufficiency as evidenced by a serum creatinine &gt; 3.0 or end-stage renal&#xD;
             disease requiring chronic dialysis.&#xD;
&#xD;
         19. Morbid obesity defined as BMI ≥ 35.&#xD;
&#xD;
         20. Subject's iliac arteries have severe calcification, tortuosity, diameter &lt;6mm, or&#xD;
             subject has had an aorto-femoral bypass.&#xD;
&#xD;
         21. Ongoing infection or sepsis.&#xD;
&#xD;
         22. Blood dyscrasias&#xD;
&#xD;
         23. Significant aortic disease.&#xD;
&#xD;
         24. Pre-existing endovascular stent graft in the supra- or infrarenal aorta or&#xD;
             pre-existing stent grafts in the ileo-femoral arteries.&#xD;
&#xD;
         25. Active peptic ulcer or has had gastrointestinal (GI) bleeding within the past 3 months&#xD;
             (≤ 90 days) prior to the index procedure.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ganesh Manoharan, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Royal Victoria Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Royal Victoria Hospital</name>
      <address>
        <city>Belfast</city>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>August 1, 2011</study_first_submitted>
  <study_first_submitted_qc>December 5, 2011</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 7, 2011</study_first_posted>
  <last_update_submitted>February 1, 2019</last_update_submitted>
  <last_update_submitted_qc>February 1, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>aortic stenosis</keyword>
  <keyword>aortic valve stenosis</keyword>
  <keyword>valvular heart disease</keyword>
  <keyword>aortic valve replacement</keyword>
  <keyword>transcatheter aortic valve implantation</keyword>
  <keyword>TAVI</keyword>
  <keyword>TAVR</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aortic Valve Stenosis</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

